MediterraneaTheranostics (MT) is a newly founded SME enrolling top representatives of medical and experimental oncology at a National and International level and with key IP assets, such as the PCT filings WO2016087651 A1 and PCT/EP2016/025148.

Mission of MT is to synergize with Oncoxx, to extend its activities and value at a global scale as an independent SME.

To this end, top-level consultants have been enrolled for business propositions in the EU, US and Asia.

The company gathers some of the best oncologists from the southern Italy. One of the main expertise of the company is related with the scientific supervision of the I, II and IIIrd stage clinical trials with reference to both diagnostics and human cancer therapeutics.

The company relies on the facilities and cutting-edge equipment provided by collaborating Academic Labs.